ProCE Banner Activity

CheckMate 9LA Post Hoc Analysis: First-line Nivolumab + Ipilimumab + CT in Patients With Advanced NSCLC and Brain Metastases

Slideset Download
Conference Coverage
First-line treatment with nivolumab plus ipilimumab plus chemotherapy was associated with improved systemic and intracranial outcomes in patients with advanced NSCLC, both with and without brain metastases at baseline.

Released: September 17, 2021

Expiration: September 16, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bayer Healthcare Pharma

Daiichi Sankyo, Inc.

Janssen administered by Scientific Affairs

Janssen Pharmaceutica NV

Millennium Pharmaceuticals Inc Subsidary of Takeda

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme